Dr. Hirsch is Professor of Medicine and Pathology at the University of Colorado School of Medicine in Denver, CO. His research interests which have spanned more than 25 years include translational research, targeted therapies, and early detection of lung cancer. Dr. Hirsch is also studying biomarkers related to molecular targeted therapies in order to understand the mechanisms of action and resistance of these new therapies, and to be able to select the patients who will benefit from such treatment. The biomarker studies relate to the development of molecular targeted therapies for chemoprevention and treatment of lung cancer including studies on lung cancer cell lines and tumor tissue from clinical cohorts. Within the last year his focus has been on identifying biomarkers, which can be used to select lung cancer patients to EGFR tyrosine kinase inhibitors and other EGFR inhibitors. Dr. Hirsch’s laboratory is currently studying biomarkers in multiple clinical trials performed in the US and Europe both in lung and head and neck cancer.
Dr. Hirsch has served on NCI’s Steering Committee for Thoracic Malignancies Program (CTEP) and is also Co-Chair for Southwest Oncology Group’s (SWOG) Lung Cancer Translational Research Committee. He also serves as Associate Director for the University of Colorado Cancer Center.
In November 2013, Dr. Hirsch became the CEO of the International Association for the Study of Lung Cancer (IASLC), the only global organization dedicated to the study of lung cancer. The IASLC’s membership includes more than 5,000 lung cancer specialists in over 100 countries. He has published more than 300 peer-reviewed scientific articles.
- Professor of Medicine and Pathology
University of Colorado, School of Medicine
University of Colorado Cancer Center